Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. G. Shapiro, E et al. ASCO Annual Meeting 2009;3500
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.